Overview

The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors

Status:
NOT_YET_RECRUITING
Trial end date:
2032-03-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of a 2-year adjuvant treatment with Ensartinib in stage I ALK-positive non-small cell lung cancer (NSCLC) patients with high-risk factors. The study population includes patients with ALK-positive NSCLC who have undergone R0 resection and have not received any postoperative treatment, with a TNM stage of I and high-risk factors for recurrence.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China